MedImmune, the biologics research and development arm of AstraZeneca, has entered into a three-year collaboration with the Clinical and Translational Science Institute (CTSI) at the University of California, SanFrancisco (UCSF). The collaboration will focus on CTSI’s Catalyst Awards program, which solicits applications from University scientists who wish to move their translational research into product development.

This marks the first industrial partnership for CTSI’s Catalyst Awards program’s therapeutic track, which focuses specifically on discovery and development of patient treatment options. The collaboration will benefit both MedImmune’s biologics and AstraZeneca’s small molecule portfolios and will call for proposals in therapeutic areas of interest to MedImmune and AstraZeneca, including cardiovascular and metabolic disease, oncology, respiratory, inflammation and autoimmunity, neuroscience and infectious disease.

Financial terms around the collaboration were not disclosed.

Source: MedImmune